18F-FSPG PET images, in comparison with MRI and 18F-FDG PET images of the three patients with lung cancer metastases to the brain.
Erik S. Mittra
Norman Koglin
Camila Mosci
Meena Kumar
Aileen Hoehne
Khun Visith Keu
Andrei H. Iagaru
Andre Mueller
Mathias Berndt
Santiago Bullich
Matthias Friebe
Heribert Schmitt-Willich
Volker Gekeler
Lüder M. Fels
Claudia Bacher-Stier
Dae Hyuk Moon
Frederick T. Chin
Andrew W. Stephens
Ludger M. Dinkelborg
Sanjiv S. Gambhir
10.1371/journal.pone.0148628.g005
https://plos.figshare.com/articles/figure/18F_FSPG_PET_images_in_comparison_with_MRI_and_18F_FDG_PET_images_of_the_three_patients_with_lung_cancer_metastases_to_the_brain_/2586631
<p>For each subject, the whole-body Maximum Intensity Projection (MIP) image of the 18F-FSPG PET scan is shown on the left. In the right column, the axial images through the level of the brain metastasis include the post-contrast T1 MRI (top), 18F-FSPG PET (middle), and 18F-FDG PET (bottom). Physiologic distribution to normal organs are highlighted on the MIP image for subject A, including the liver (l), pancreas (p), kidneys (k), and bladder (b). For the first two subjects (A, B), the small lesions (below 1.5 cm) are clearly visible on MRI and with 18F-FSPG (SUV-A: 11.0, SUV-B: 4.7). With 18F-FDG, however, there is no discernible activity in these lesions. The larger lesion for subject C, who had previously been treated in this region, is again clearly discernable with MRI although the etiology of the enhancement was unclear whether representing residual/recurrent disease versus post-therapy changes. Both the 18F-FDG (SUV 10.1) and 18F-FSPG PET (SUV 21.8) are positive for this subject, but the accumulation of the latter is stronger, and further enhanced by the lack of uptake in the surrounding normal brain tissue (FDG SUV 4.8, FSPG SUV 0.1).</p>
2016-02-18 15:54:50
measure xC
imaging orthotopic brain tumors
ratio
orthotopic brain tumors
safety parameters
metastatic brain cancer
intracranial malignancies
tumor uptake
brain metastases
future studies
subject
GS 9L model
300 MBq
Fischer rats
glutamate analogue
tumor visualization
brain tumors
age 50.4 years
Clinical Evaluation
animal study
CT
Positron Emission Tomography
animal model.Conclusions 18F
scan
background signal
Pilot Preclinical
GS 9L glioblastoma cells
intracranial malignancies.Experimental DesignFor
brain tumor
transporter activity
pilot study
NCT
novel PET